Which has preferable earnings and valuation, INVA or LGND?

Innoviva has higher revenue and earnings than Ligand Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.99 $271.17M $6.01 3.70 Ligand Pharmaceuticals $268.09M 23.64 $124.45M $7.37 42.91

Does the media favor INVA or LGND?

In the previous week, Ligand Pharmaceuticals had 11 more articles in the media than Innoviva. MarketBeat recorded 14 mentions for Ligand Pharmaceuticals and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.11 beat Ligand Pharmaceuticals' score of 0.95 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, INVA or CLDX?

Innoviva has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.99 $271.17M $6.01 3.70 Celldex Therapeutics $1.54M 1,993.34 -$258.76M -$4.26 N/A

Does the media prefer INVA or BCRX?

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for BioCryst Pharmaceuticals and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.11 beat BioCryst Pharmaceuticals' score of 0.79 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ZBIO or INVA?

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zenas BioPharma $10M 181.44 -$377.74M -$8.47 N/A Innoviva $411.33M 3.99 $271.17M $6.01 3.70

Does the media favor ZBIO or INVA?

In the previous week, Zenas BioPharma had 1 more articles in the media than Innoviva. MarketBeat recorded 4 mentions for Zenas BioPharma and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.11 beat Zenas BioPharma's score of 0.00 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, INVA or NVAX?

Novavax has higher revenue and earnings than Innoviva. Novavax is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.99 $271.17M $6.01 3.70 Novavax $1.12B 1.37 $440.30M -$0.58 N/A

Is INVA or NVAX more profitable?

Innoviva has a net margin of 119.89% compared to Novavax's net margin of -14.73%. Innoviva's return on equity of 33.33% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 119.89% 33.33% 22.67% Novavax -14.73% -14.82% 1.23%

Does the media refer more to INVA or NVAX?

In the previous week, Novavax had 19 more articles in the media than Innoviva. MarketBeat recorded 22 mentions for Novavax and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.11 beat Novavax's score of 0.71 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Innoviva (INVA) Competitors

$22.24 +0.04 (+0.18%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$22.24 0.00 (0.00%)

As of 07/10/2026 04:39 PM Eastern

Compare

INVA vs. LGND, CLDX, BCRX, ZBIO, and NVAX

Should you buy Innoviva stock or one of its competitors? MarketBeat compares Innoviva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Innoviva include Ligand Pharmaceuticals (LGND), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

How does Innoviva compare to Ligand Pharmaceuticals?

Innoviva (NASDAQ:INVA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Innoviva has higher revenue and earnings than Ligand Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.99	$271.17M	$6.01	3.70
Ligand Pharmaceuticals	$268.09M	23.64	$124.45M	$7.37	42.91

In the previous week, Ligand Pharmaceuticals had 11 more articles in the media than Innoviva. MarketBeat recorded 14 mentions for Ligand Pharmaceuticals and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.11 beat Ligand Pharmaceuticals' score of 0.95 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Innoviva has a net margin of 119.89% compared to Ligand Pharmaceuticals' net margin of 55.95%. Innoviva's return on equity of 33.33% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Innoviva presently has a consensus price target of $36.20, suggesting a potential upside of 62.77%. Ligand Pharmaceuticals has a consensus price target of $292.86, suggesting a potential downside of 7.39%. Given Innoviva's higher possible upside, analysts clearly believe Innoviva is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Innoviva and Ligand Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Innoviva compare to Celldex Therapeutics?

Innoviva (NASDAQ:INVA) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Innoviva has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Innoviva presently has a consensus target price of $36.20, indicating a potential upside of 62.77%. Celldex Therapeutics has a consensus target price of $49.30, indicating a potential upside of 26.05%. Given Innoviva's higher possible upside, research analysts plainly believe Innoviva is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Innoviva has a net margin of 119.89% compared to Celldex Therapeutics' net margin of 0.00%. Innoviva's return on equity of 33.33% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Innoviva has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.99	$271.17M	$6.01	3.70
Celldex Therapeutics	$1.54M	1,993.34	-$258.76M	-$4.26	N/A

99.1% of Innoviva shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Innoviva had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 3 mentions for Innoviva and 1 mentions for Celldex Therapeutics. Innoviva's average media sentiment score of 1.11 beat Celldex Therapeutics' score of 0.00 indicating that Innoviva is being referred to more favorably in the media.

Company	Overall Sentiment
Innoviva	Positive
Celldex Therapeutics	Neutral

Summary

Innoviva beats Celldex Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Innoviva compare to BioCryst Pharmaceuticals?

Innoviva (NASDAQ:INVA) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

99.1% of Innoviva shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Innoviva has a net margin of 119.89% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Innoviva's return on equity of 33.33% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Innoviva has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.99	$271.17M	$6.01	3.70
BioCryst Pharmaceuticals	$885.72M	3.00	$263.86M	-$1.78	N/A

Innoviva has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for BioCryst Pharmaceuticals and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.11 beat BioCryst Pharmaceuticals' score of 0.79 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva currently has a consensus target price of $36.20, suggesting a potential upside of 62.77%. BioCryst Pharmaceuticals has a consensus target price of $21.78, suggesting a potential upside of 108.40%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Innoviva and BioCryst Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Innoviva compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Innoviva has a net margin of 119.89% compared to Zenas BioPharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Innoviva	119.89%	33.33%	22.67%

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	181.44	-$377.74M	-$8.47	N/A
Innoviva	$411.33M	3.99	$271.17M	$6.01	3.70

Zenas BioPharma has a beta of -0.96, suggesting that its stock price is 196% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

99.1% of Innoviva shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 2.0% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Zenas BioPharma had 1 more articles in the media than Innoviva. MarketBeat recorded 4 mentions for Zenas BioPharma and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.11 beat Zenas BioPharma's score of 0.00 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zenas BioPharma presently has a consensus price target of $44.29, indicating a potential upside of 54.09%. Innoviva has a consensus price target of $36.20, indicating a potential upside of 62.77%. Given Innoviva's stronger consensus rating and higher possible upside, analysts clearly believe Innoviva is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Innoviva beats Zenas BioPharma on 12 of the 16 factors compared between the two stocks.

How does Innoviva compare to Novavax?

Innoviva (NASDAQ:INVA) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Innoviva has a net margin of 119.89% compared to Novavax's net margin of -14.73%. Innoviva's return on equity of 33.33% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Novavax	-14.73%	-14.82%	1.23%

In the previous week, Novavax had 19 more articles in the media than Innoviva. MarketBeat recorded 22 mentions for Novavax and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.11 beat Novavax's score of 0.71 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Innoviva currently has a consensus price target of $36.20, suggesting a potential upside of 62.77%. Novavax has a consensus price target of $13.00, suggesting a potential upside of 39.34%. Given Innoviva's stronger consensus rating and higher possible upside, equities research analysts clearly believe Innoviva is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

Innoviva has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Novavax has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

Novavax has higher revenue and earnings than Innoviva. Novavax is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.99	$271.17M	$6.01	3.70
Novavax	$1.12B	1.37	$440.30M	-$0.58	N/A

99.1% of Innoviva shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Innoviva beats Novavax on 11 of the 16 factors compared between the two stocks.

Get Innoviva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INVA vs. The Competition

Export

Metric	Innoviva	Large Cap Pharma Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.64B	$333.45B	$7.12B	$12.61B
Dividend Yield	N/A	2.68%	2.68%	7.83%
P/E Ratio	3.70	29.70	27.19	24.56
Price / Sales	3.99	5.41	591.20	121.87
Price / Cash	4.41	14.20	49.34	60.04
Price / Book	1.42	8.37	10.88	6.39
Net Income	$271.17M	$11.61B	$3.58B	$331.76M
7 Day Performance	-0.31%	-2.39%	-0.27%	0.37%
1 Month Performance	-0.89%	5.82%	4.51%	0.53%
1 Year Performance	18.49%	27.26%	29.15%	21.93%

Innoviva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INVA Innoviva	3.6625 of 5 stars	$22.24 +0.2%	$36.20 +62.8%	+16.7%	$1.64B	$411.33M	3.70	100	Positive News High Trading Volume
LGND Ligand Pharmaceuticals	3.2924 of 5 stars	$319.55 flat	$257.71 -19.4%	+153.0%	$6.40B	$268.09M	43.36	80	News Coverage Analyst Forecast
CLDX Celldex Therapeutics	1.7981 of 5 stars	$38.37 flat	$49.30 +28.5%	+72.4%	$3.01B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	3.1323 of 5 stars	$9.84 flat	$21.67 +120.2%	+17.7%	$2.50B	$874.84M	N/A	530	News Coverage Analyst Forecast
ZBIO Zenas BioPharma	3.1653 of 5 stars	$27.23 flat	$44.29 +62.6%	+138.1%	$1.72B	N/A	N/A	N/A	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INVA) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innoviva (INVA) Competitors

INVA vs. LGND, CLDX, BCRX, ZBIO, and NVAX

How does Innoviva compare to Ligand Pharmaceuticals?

Summary

How does Innoviva compare to Celldex Therapeutics?

Summary

How does Innoviva compare to BioCryst Pharmaceuticals?

Summary

How does Innoviva compare to Zenas BioPharma?

Summary

How does Innoviva compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innoviva (INVA) Competitors

INVA vs. LGND, CLDX, BCRX, ZBIO, and NVAX

How does Innoviva compare to Ligand Pharmaceuticals?

Do insiders and institutionals have more ownership in INVA or LGND?

Which has preferable earnings and valuation, INVA or LGND?

Does the media favor INVA or LGND?

Which has more volatility and risk, INVA or LGND?

Is INVA or LGND more profitable?

Do analysts recommend INVA or LGND?

Summary

How does Innoviva compare to Celldex Therapeutics?

Which has more volatility & risk, INVA or CLDX?

Do analysts rate INVA or CLDX?

Is INVA or CLDX more profitable?

Which has stronger earnings and valuation, INVA or CLDX?

Do institutionals & insiders believe in INVA or CLDX?

Does the media prefer INVA or CLDX?

Summary

How does Innoviva compare to BioCryst Pharmaceuticals?

Do institutionals and insiders hold more shares of INVA or BCRX?

Is INVA or BCRX more profitable?

Which has better earnings and valuation, INVA or BCRX?

Which has more volatility and risk, INVA or BCRX?

Does the media prefer INVA or BCRX?

Do analysts recommend INVA or BCRX?

Summary

How does Innoviva compare to Zenas BioPharma?

Is ZBIO or INVA more profitable?

Which has stronger earnings & valuation, ZBIO or INVA?

Which has more volatility and risk, ZBIO or INVA?

Do institutionals & insiders have more ownership in ZBIO or INVA?

Does the media favor ZBIO or INVA?

Do analysts prefer ZBIO or INVA?

Summary

How does Innoviva compare to Novavax?

Is INVA or NVAX more profitable?

Does the media refer more to INVA or NVAX?

Do analysts rate INVA or NVAX?

Which has more risk and volatility, INVA or NVAX?

Which has higher earnings & valuation, INVA or NVAX?

Do insiders & institutionals believe in INVA or NVAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools